Shaohua Y. Li
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Systemic Treatment Patterns and Clinical Outcomes in Hepatocellular Carcinoma: A Multicenter Real-World Study from China (STAR-HCC).
Journal: JHEP reports : innovation in hepatology
Published: March 21, 2026
DLGAP5 regulates malignancy and lenvatinib sensitivity of hepatocellular carcinoma through AKT/mTOR/NF-κB pathway.
Journal: European journal of medical research
Published: August 04, 2025
Transarterial chemoembolization versus hepatic arterial infusion chemotherapy as first treatment for hepatocellular carcinoma with macrovascular invasion.
Journal: International journal of medical sciences
Published: December 04, 2024
AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection.
Journal: JHEP reports : innovation in hepatology
Published: September 20, 2024
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: September 13, 2024
FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study.
Journal: Journal of hepatocellular carcinoma
Published: September 10, 2024
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: September 05, 2024
Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma.
Journal: American journal of cancer research
Published: August 28, 2024
The ARH score, a practical guide to decision-making for retreatment with hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients.
Journal: International immunopharmacology
Published: March 26, 2024
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
Journal: Frontiers in immunology
Published: March 08, 2024
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma.
Journal: British journal of cancer
Published: March 03, 2024
Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: August 27, 2023
Last Updated: 09/26/2026